Elmiron®, manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals, is prescribed to those suffering from interstitial cystitis in hopes of reducing chronic bladder pain.
The American Academy of Ophthalmology released research at a 2019 conference that highlighted an association between the use of the prescription drug Elmiron® (pentosan polysulfate sodium) for a period of at least six months and the development of pigmentary maculopathy—a medical condition that can lead to permanent vision loss and potentially total blindness
It is estimated that approximately 25% of long-term Elmiron patients could suffer from ocular damage. However, this condition is difficult to diagnose and incorrect initial diagnoses are common. For this reason, medical professionals are suggesting continued or repeated testing to determine if such a condition exists and investigate its cause.
The early stages of maculopathy may present through difficulty reading or seeing other close objects, a generalized dimming or difficulty adjusting to changes in light, dark spots, and blurred vision.
If you or someone you love has been diagnosed with a form of maculopathy or other ocular damage after having used Elmiron for at least six months, we urge you to contact our firm, Slater Slater Schulman LLP, to obtain a free case evaluation as to whether you qualify to file a claim seeking compensation from the manufacturers of Elmiron. Please call 800-251-6990 or fill out our online form to begin our investigation.
